Milrinon Abcur (Milrinone)

Milrinone, the active ingredient in Milrinon Abcur, is a phosphodiesterase‑3 inhibitor presented as an intravenous formulation for hospital use. It is employed to improve cardiac contractility in acute decompensated heart failure and cardiogenic shock. GNH USA supplies Milrinon Abcur as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Milrinone acts as a selective phosphodiesterase‑3 inhibitor to increase cardiac output in critical heart conditions. Acute decompensated heart failure: improves contractility and reduces pulmonary congestion. Cardiogenic shock: provides rapid inotropic support to maintain systemic perfusion. Low‑output cardiac states after surgery: enhances myocardial performance and stabilises haemodynamics.

Milrinone may be associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Hypotension: reduction in systemic blood pressure. - Tachyarrhythmias: increased heart rate or irregular rhythm. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Flushing: transient warmth and redness of the skin. - Diarrhoea: loose stools in some patients.

Serious or Rare Side Effects: - Ventricular arrhythmias: potentially life‑threatening rhythm disturbances. - Severe hypotension: marked drop in blood pressure requiring intervention. - Myocardial ischaemia: reduced coronary blood flow leading to chest pain. - Thrombocytopenia: low platelet count increasing bleeding risk. - Anaphylactic reactions: rare but severe allergic responses. - Hepatic dysfunction: abnormal liver enzyme elevations.

Milrinon Abcur requires careful clinical monitoring due to its potent cardiovascular effects. - Blood pressure monitoring: check systolic and diastolic values frequently. - Cardiac rhythm surveillance: continuous ECG is recommended during infusion. - Renal function assessment: dose may need adjustment in impaired clearance. - Contraindication in severe aortic stenosis: avoid due to risk of outflow obstruction. - Hypersensitivity screening: discontinue if allergic reaction occurs. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Milrinon Abcur can interact with several drug classes, influencing its safety and efficacy.

Major Interactions (Avoid): - Other phosphodiesterase‑3 inhibitors: additive inotropic and vasodilatory effects may cause severe hypotension. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase milrinone plasma concentrations, raising toxicity risk. - Concurrent vasodilators (e.g., nitroprusside): may precipitate profound hypotension.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt the desired inotropic response. - Diuretics: electrolyte shifts can predispose to arrhythmias. - Anticoagulants: enhanced bleeding tendency may occur.